Company news

Mabwell (shanghai) Bioscience Co., Ltd. Class A (SSE:688062) news

Mabwell (shanghai) Bioscience Co., Ltd. Class A news releases on 6ix. Latest, Sep 29, 2026: (688062)"MABWELL (SHANGHAI) BIOSCIENCE CO., LTD."Announcement…

Mabwell (shanghai) Bioscience Co., Ltd. Class A (SSE:688062) news

Press releases & updates

(688062)"MABWELL (SHANGHAI) BIOSCIENCE CO., LTD."Announcement on External Investment and Introduction of Investors to Lianwei Chuangyuan

"MABWELL (SHANGHAI) BIOSCIENCE CO., LTD."Announcement on Resolutions of the 3rd Meeting of the 3rd Board of Directors

"MABWELL (SHANGHAI) BIOSCIENCE CO., LTD."Announcement on Resolutions of the 4th Extraordinary General Meeting in 2026

ERS 2026 | Mabwell Presents Phase Ib/IIa Clinical Results of Anti-ST2 Monoclonal Antibody 9MW1911 in COPD Patients

"MABWELL (SHANGHAI) BIOSCIENCE CO., LTD."Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry

"MABWELL (SHANGHAI) BIOSCIENCE CO., LTD."Special Report on the Deposit and Actual Use of Raised Funds for the First Half of 2026

Second PIC/S GMP Certification | Mabwell Passes Brazilian GMP Inspection for Its Denosumab Injections

"MABWELL (SHANGHAI) BIOSCIENCE CO., LTD."Announcement on Voluntary Disclosure of the Approval by the National Medical Products Administration of the Clinical Trial Application for 9MW5211 Injection

Announcement on Listing and Circulation of Partial Restricted Shares in Initial Public Offering

Announcement on Voluntary Disclosure of Clinical Trial Applications for 9MW5211 Injection Approved by China NMPA

Mabwell Receives IND Clearance from NMPA for LILRB4/CD3-targeting TCE Bispecific Antibody 6MW5311

Announcement on Convening Performance Briefing for 2025 and Q1 2026

Mabwell Presents Clinical Results of Nectin-4-Targeting ADC 9MW2821 at 2026 ESMO Gynaecological Cancers Congress

Announcement on Voluntary Disclosure of FDA Approval for the Clinical Trial Application for 6MW5311 Injection

Mabwell's 9MW5211 Receives IND Clearance from NMPA for Inflammatory Bowel Disease

Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026

Announcement on Engagement of H-share Audit Institution for 2026

Mabwell Announces Latest Clinical Data on 9MW2821 to Be Presented at 2026 ASCO Annual Meeting as Oral and Poster Presentations

Mabwell Announces NMPA Approval of Supplemental Application for Additional Indications of MAIWEIJIAN (Denosumab Injection)

World's First | Mabwell's 9MW5211 Receives FDA Clearance for Clinical Trial Application

Notice on Convening the 2nd Extraordinary General Meeting in 2026

2026 ESMO GC | Mabwell to Present Latest Clinical Data on 9MW2821 for Cervical Cancer in Oral and Poster Presentations

Report for Q1 2026

Announcement on the Public Offering Price of Overseas Listed Foreign Shares (H-shares)

2026 ASCO | Mabwell to Present Latest Clinical Data on 9MW2821 Combined with Toripalimab for Urothelial Carcinoma in Oral and Poster Presentations

Case Report of Mabwell's Nectin-4 targeting ADC (9MW2821) in Cervical Cancer Published in The New England Journal of Medicine

Mabwell Passes On-site GMP Inspection by Regulatory Authority of PIC/S Member Country (Jordan) for the First Time

Announcement on Voluntary Disclosure of Acceptance Supplementary Application for Increasing the Indications of Denosumab Injection (MAIWEIJIAN)

Announcement on Resolutions of the 30th Meeting of the 2nd Board of Directors

2025 Annual Report

Announcement on the Results of Issuance of the 2026 Phase I Targeted Science and Technology Innovation Bonds

Announcement on Preliminary Earnings Estimate for 2025

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

Notice on Convening the 1st Extraordinary General Meeting in 2026

Earnings Preannouncement for 2025

Mabwell Announces First-Patient Dosed in Clinical Trial of Novel CDH17-Targeting ADC 7MW4911 in the U.S.

Announcement on Continuing to Use Some Temporarily Idle Raised Funds for Cash Management

Mabwell's Adalimumab Biosimilar Receives Marketing Approval in Indonesia

Mabwell Announces First Patient Dosed in Phase II Trial of Anti-IL-11 Antibody for Pathological Scarring

Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025

Mabwell Receives IND Clearance for Novel Anti-ST2 Monoclonal Antibody 9MW1911 to Initiate Phase IIa Study

Announcement on Implementation Results of Share Repurchase

Mabwell Announces First Overseas Commercial Shipment of Denosumab Injection

Announcement on Resolutions of the 26th Meeting of the 2nd Board of Directors

Annualized Severe COPD Exacerbation Rate Reduced by Over 40%: Mabwell Announces Phase IIa Results for Innovative Anti-ST2 Antibody 9MW1911

Announcement on Voluntary Disclosure of the Clinical Research Progress in 9MW1911

Announcement on Opening and Modifying Certain Special Accounts for Raised Funds and Re-Signing the Tripartite and Quadripartite Supervision Agreements

Mabwell Announces First-Patient Dosing for Novel CDH17-Targeting ADC 7MW4911

Mabwell's Novel Anti‑IL‑11 Monoclonal Antibody 9MW3811 Approved by NMPA to Initiate Phase II Clinical Trial in Pathological Scarring

Announcement on Voluntary Disclosure of Clinical Trial Applications for 9MW3811 Injection Approved by China NMPA